CanSino Biologics Inc
CanSino Biologics Inc. develops, manufactures, and commercializes vaccines in the People's Republic of China. The company develops Convidecia and the Ad5-nCoV for Inhalation vaccines to recombinant novel coronavirus disease; Ad5-EBOV, an Ebola virus vaccine; and MCV2 and MCV4 vaccines for the prevention of N. meningitides. It develops DTcP vaccine for infants and DTcP Booster vaccine, which are i… Read more
CanSino Biologics Inc (CASBF) - Total Liabilities
Latest total liabilities as of September 2025: $2.37 Billion USD
Based on the latest financial reports, CanSino Biologics Inc (CASBF) has total liabilities worth $2.37 Billion USD as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
CanSino Biologics Inc - Total Liabilities Trend (2016–2024)
This chart illustrates how CanSino Biologics Inc's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
CanSino Biologics Inc Competitors by Total Liabilities
The table below lists competitors of CanSino Biologics Inc ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Henan Tong-Da Cable Co Ltd
SHE:002560
|
China | CN¥2.63 Billion |
|
Wuhan Thalys Med Tech Co Ltd
SHG:603716
|
China | CN¥1.04 Billion |
|
R R Kabel Limited
NSE:RRKABEL
|
India | ₹13.38 Billion |
|
CANWEL BLDG MATL
F:2CW
|
Germany | €1.25 Billion |
|
HANOF
PINK:HANOF
|
USA | $221.29 Million |
|
Lander Sports Development Co Ltd
SHE:000558
|
China | CN¥1.40 Billion |
Liability Composition Analysis (2016–2024)
This chart breaks down CanSino Biologics Inc's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.62 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.48 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.32 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how CanSino Biologics Inc's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for CanSino Biologics Inc (2016–2024)
The table below shows the annual total liabilities of CanSino Biologics Inc from 2016 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | $3.05 Billion | -24.39% |
| 2023-12-31 | $4.03 Billion | -4.55% |
| 2022-12-31 | $4.22 Billion | +26.97% |
| 2021-12-31 | $3.33 Billion | +391.17% |
| 2020-12-31 | $677.22 Million | +115.69% |
| 2019-12-31 | $313.98 Million | +6.96% |
| 2018-12-31 | $293.56 Million | +13.33% |
| 2017-12-31 | $259.03 Million | +131.90% |
| 2016-12-31 | $111.70 Million | -- |